Please use this identifier to cite or link to this item:
Title: MAB-MIG: Registry of the Spanish Neurological Society of erenumab for migraine prevention
Filiation: Servicio de Neurología. Hospital Universitario de Fuenlabrada
Decs: Anticuerpos Monoclonales Humanizados
Trastornos Migrañosos
Issue Date: 17-Jul-2021
Citation: J Headache Pain.2021 Jul;(22)1:74
Abstract: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results.
PMID: 34273947
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
Journal Headache Pain.pdf761.94 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons